To explore whether the combination of vascular normalization (using a non-VEGF inhibitor) and immunotherapy could block the development of liver cancer, DEN-treated mice were treated with a combination of CD5-2 and anti-PD1 antibody or their respective controls. This evidence concerns the gene CD52 and liver cancer.